This personalized approach may also guide dose adjustments, choice of compound (agonist vs. PAM), and even prediction of adverse effects, thus enhancing the clinical utility and translational success of α7-nAChR-targeted therapies in neurodegenerative diseases. Here, CHRNA7 is linked to neurodegenerative disease.